Is CSBR fairly valued? Test your thesis with our free DCF calculator.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Is there any change in the strategy for the data licensing business model or go-to-market approach? A: Robert Brainin, CEO: There are no changes to the strategy at this time. It's still early, but we've had some early wins and see a lot of potential. Customer engagement is strong, and we have a growing pipeline. We'll continue to update as we gain traction.
Q: How would you characterize the size of the opportunity for the data business relative to the traditional business? A: Robert Brainin, CEO: It's still early to predict the exact size and success of this opportunity. We know there's potential and interest, especially as this data feeds AI and ML models in drug discovery. We'll find out more as we execute on these deals.